Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sugen LLC

Latest From Sugen LLC

New Therapeutic Targets & A Rich Year For Approvals: EMA’s PRIME In 2020

Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.

Research & Development Pink Sheet Perspectives

Mogrify: Using Big Data To Transform Development Of Cell Therapies

Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.

C-Suite Speaks Commercial

Chastened Innate Returns Lumoxiti Rights To AZ

The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.

Cancer Drug Review

Early EU Approval Wins In Line For Daiichi/AZ & Lilly

Advanced breast cancer treatment Enhertu and non-small cell lung cancer and thyroid cancer therapy Retsevmo are set to win conditional marketing authorizations in the EU shortly. The two drugs are among a number of new products that the European Medicines Agency has just recommended for approval.

Europe Approvals
See All

Company Information

UsernamePublicRestriction

Register